Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study

• Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in combination with avelumab in bladder cancer study.

• The Phase 2 JAVELIN Bladder Medley study will include locally advanced or metastatic urothelial carcinoma (UC) patients.

• NKTR-255 is wholly owned by Nektar and is currently being evaluated in two separate clinical studies in both liquid and solid tumors.

• Avelumab is marketed in the U.S. as Bavencio, is co-developed and co-commercialized by Merck KGaA and Pfizer.

• The study will begin enrolling patients in Q1 of 2022.

• Price Action: NKTR shares are up 4.53% at $17.08 during the market session on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• Why Did Deutsche Bank Downgrade This Big Pharma Stock?

• Pfizer/BioNTech COVID-19 Vaccine Data For Kids Is Here: What You Need To Know

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.